The impact of hepatitis C burden: an evidence‐based approach

@article{Younossi2014TheIO,
  title={The impact of hepatitis C burden: an evidence‐based approach},
  author={Z Younossi and Fasiha Kanwal and Sammy Saab and K. A. Brown and H. B. El‐Serag and W. R. Kim and A Ahmed and Marcelo Kugelmas and Staurt C Gordon},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2014},
  volume={39}
}
Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon‐free therapies… Expand
Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review.
TLDR
The authors will consider the emerging data showing that curative therapy with DAAs can prevent HCV-related morbidity and mortality, with a focus on patients with HCV -related cirrhosis. Expand
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
TLDR
It is critical to assess the total benefits of sustained virological response in a comprehensive manner to account for the improvement of patient reported health and economic outcomes of HCV cure. Expand
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
  • Z. Younossi, L. Henry
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2014
TLDR
Insight is offered into the other key and equally important outcomes (PRO's, HRQOL and cost) which should be considered when assessing the applicability of these new regimens for the care of patients infected with HCV. Expand
Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens
TLDR
PROs assess patients' health‐related quality of life (HRQOL) especially in the realms of fatigue and neuropsychiatric issues such as depression which can affect treatment adherence and work productivity. Expand
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
TLDR
This review will summarize the data regarding these interferon-free regimens, including Gilead's Harvoni (sofosbuvir/ledipasvir), AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen’s Olysio (simeprevir) with sofOSbuvir. Expand
Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan
TLDR
Treatment of HCV GT1b with all‐oral direct‐acting anti‐virals in Japan can lead to significant direct and indirect savings related to avoidance of HCC and DCC. Expand
Interferon‐free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis
TLDR
In a controlled study, interferon‐based therapy was associated with a lower virological response in vasculitic patients than in patients without vasculitis. Expand
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
TLDR
There is a significant survival benefit of achieving an sustained virologic response compared with unsuccessful treatment in the general hepatitis C virus-infected population. Expand
Using the endoscopy suite of an urban medical center for efficient identification of patients with HCV and linkage to care
TLDR
Optimizing strategies to identify patients with HCV and link them to care would be expected to pay high dividends with respect to public health. Expand
The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data
TLDR
It was found that despite the introduction of the breakthrough designated triple therapies with telaprevir or boceprevir in 2011, there was no increase of prevalence or incidence between 2010 and 2011. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 124 REFERENCES
Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C.
TLDR
Lack of awareness about the prevalence of chronic viral hepatitis in the United States and about the proper methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C probably contributes to continuing transmission. Expand
Natural history of acute and chronic hepatitis C.
TLDR
Personalized treatment approaches for HCV infection should consider individual risk profiles to avoid both under- and over-treatment - which will remain important also in upcoming era of interferon-free treatment of hepatitis C. Expand
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
TLDR
An SVR reduced mortality among patients infected with HCV of genotypes 1, 2, or 3 who were being treated by routine medical practice and had substantial comorbidities. Expand
Economic burden associated with patients diagnosed with hepatitis C.
TLDR
A diagnosis of HCV infection was correlated significantly with increased adverse event risk and increased health care costs and new alternative treatments are needed that are more efficacious and less burdensome for the patient. Expand
Economic burden of hepatitis C‐associated diseases in the United States
TLDR
The objective of this study was to assess the economic burden data sources for hepatitis C in the United States and found that most studies traced back to a handful of publications in the 1990s, which have provided the basis for all sequelae‐based cost estimates to date. Expand
Interferon-Free Hepatitis C Therapy
TLDR
The article discusses difficulties with new drug development and provides an opinion on the research issues still to be dealt with and the requirements for the successful implementation of such a strategy, including lack of efficacy in certain populations, unexpected side effects, antiviral resistance, late relapse and cost. Expand
Impact of hepatitis C virus infection on all‐cause and liver‐related mortality in a large community‐based cohort of inner city residents
TLDR
This study demonstrates a high rate of mortality in this population, particularly those with HIV, and HCV‐infected inner city residents >50’years of age were at significant risk of liver‐related mortality. Expand
Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
TLDR
In the hepatitis C group, the proportion of liver disease-related death was markedly higher, and the survival rate lower, than the general resident group, and introduction of IFN treatment in <70-year-old patients with hepatitis C without LC or HCC improved the survival rates to a level comparable to that of the general residents. Expand
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.
TLDR
The prevalence of cirrhosis and HCC in HCV-infected patients has increased significantly over the past 10 years, and an aging cohort of patients with HCV could partly explain these findings. Expand
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
TLDR
Results indicate sustained virological response causes a two‐thirds reduction in the risk of type 2 diabetes development in HCV‐positive patients treated with IFN. Expand
...
1
2
3
4
5
...